Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized adjudicator-blinded study of olorofim versus liposomal amphotericin B plus standard of care for invasive fungal disease caused by Aspergillus
CTR20233019Phase 3Active
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olorofim in invasive aspergillosis (IA), invasive mycoses, sponsored by Shionogi & Co., Ltd.. Started Mar 2024; status: active.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)invasive mycoses
Beyond the preview
Go deeper on CTR20233019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233019.